NASDAQ: $JAZZ A Major Milestone in Oncology The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Ziihera (zanidatamab-hrii), marking a significant advancement for patients battling a specific, challenging form of cancer. This targeted therapy is now approved for the treatment of adult patients with unresectable or metastatic HER2-positive biliary tract cancer (BTC).…